MX387330B - Composiciones y metodos para el tratamiento de sindrome de intestino irritable - Google Patents

Composiciones y metodos para el tratamiento de sindrome de intestino irritable

Info

Publication number
MX387330B
MX387330B MX2019001360A MX2019001360A MX387330B MX 387330 B MX387330 B MX 387330B MX 2019001360 A MX2019001360 A MX 2019001360A MX 2019001360 A MX2019001360 A MX 2019001360A MX 387330 B MX387330 B MX 387330B
Authority
MX
Mexico
Prior art keywords
formula
compositions
treatment
bowel syndrome
irritable bowel
Prior art date
Application number
MX2019001360A
Other languages
English (en)
Spanish (es)
Other versions
MX2019001360A (es
Inventor
Mahesh Kandula
Original Assignee
Cellix Bio Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Private Ltd filed Critical Cellix Bio Private Ltd
Publication of MX2019001360A publication Critical patent/MX2019001360A/es
Publication of MX387330B publication Critical patent/MX387330B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C15/00Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic parts
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/55Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/14Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of carbon skeletons containing rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2019001360A 2016-08-11 2017-04-19 Composiciones y metodos para el tratamiento de sindrome de intestino irritable MX387330B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201641027529 2016-08-11
PCT/IB2017/052233 WO2018029545A1 (en) 2016-08-11 2017-04-19 Compositions and methods for the treatment of irritable bowel syndrome

Publications (2)

Publication Number Publication Date
MX2019001360A MX2019001360A (es) 2019-06-03
MX387330B true MX387330B (es) 2025-03-18

Family

ID=61163212

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001360A MX387330B (es) 2016-08-11 2017-04-19 Composiciones y metodos para el tratamiento de sindrome de intestino irritable

Country Status (14)

Country Link
US (2) US11078154B2 (de)
EP (1) EP3481383B1 (de)
JP (1) JP2019524796A (de)
KR (1) KR20190039723A (de)
CN (1) CN109640965A (de)
AU (1) AU2017308801B2 (de)
CA (1) CA3031893A1 (de)
IL (1) IL264467B (de)
MX (1) MX387330B (de)
NZ (1) NZ750126A (de)
RU (1) RU2751770C2 (de)
SG (2) SG10202101247QA (de)
WO (1) WO2018029545A1 (de)
ZA (1) ZA201900466B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3746451B1 (de) * 2018-02-02 2023-07-12 Boehringer Ingelheim International GmbH Benzyl-, (pyridin-3-yl)methyl- oder (pyridin-4-yl)methyl-substituierte oxadiazolopyridinderivate als inhibitoren der ghrelin-o-acyl-transferase (goat)
CN113398112A (zh) * 2021-06-17 2021-09-17 西南医科大学 FA介导的BBA/CM-β-CD靶向递药系统、制备方法及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
CN1044364C (zh) * 1993-06-26 1999-07-28 河南师范大学 一种治疗肠炎和溃疡性结肠炎的药物及其制备工艺
IL113459A (en) 1995-04-23 2000-07-16 Electromagnetic Bracing System Electrophoretic cuff apparatus
US6239180B1 (en) 1995-11-08 2001-05-29 The Regents Of The University Of California Transdermal therapeutic device and method with capsaicin and capsaicin analogs
EP0968711B9 (de) 1997-10-28 2008-05-28 Bando Chemical Industries, Ltd. Dermatologisches pflaster und verfahren zur herstellung seiner basisschicht
US6103275A (en) 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
DE19827732A1 (de) 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
US6312716B1 (en) 1999-05-10 2001-11-06 Peierce Management Llc Patch and method for transdermal delivery of bupropion base
US6974588B1 (en) 1999-12-07 2005-12-13 Elan Pharma International Limited Transdermal patch for delivering volatile liquid drugs
WO2006125293A1 (en) * 2005-05-27 2006-11-30 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
CN101365428B (zh) * 2006-01-05 2012-08-29 威洛克塞斯药物股份公司 可负载崩解片剂
KR101708065B1 (ko) * 2008-07-08 2017-02-17 카타베이시스 파마슈티칼즈, 인코포레이티드 지방산 아세틸화 살리실레이트 및 그 용도
AU2010234206B2 (en) * 2009-04-06 2016-10-27 Crearene Ag Hemodialysis and peritoneal dialysis solutions comprising one or more creatine compounds
IT1400119B1 (it) * 2010-05-24 2013-05-17 Sofar Spa Nuovi derivati della mesalazina, processo di sintesi ed uso nel trattamento di malattie infiammatorie intestinali.
WO2013175357A2 (en) * 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of inflammatory bowel disease
WO2014091384A2 (en) * 2012-12-12 2014-06-19 Mahesh Kandula Compositions and methods for the treatment of mucositis
US9333187B1 (en) * 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease

Also Published As

Publication number Publication date
MX2019001360A (es) 2019-06-03
RU2019101849A3 (de) 2020-09-11
EP3481383A1 (de) 2019-05-15
WO2018029545A1 (en) 2018-02-15
NZ750126A (en) 2022-07-01
CA3031893A1 (en) 2018-02-15
KR20190039723A (ko) 2019-04-15
US11078154B2 (en) 2021-08-03
JP2019524796A (ja) 2019-09-05
SG11201900588YA (en) 2019-02-27
US20220162156A1 (en) 2022-05-26
RU2019101849A (ru) 2020-09-11
AU2017308801B2 (en) 2022-03-10
EP3481383B1 (de) 2023-06-14
RU2751770C2 (ru) 2021-07-16
AU2017308801A1 (en) 2019-02-07
CN109640965A (zh) 2019-04-16
IL264467B (en) 2021-09-30
EP3481383A4 (de) 2020-03-18
US20190177267A1 (en) 2019-06-13
IL264467A (en) 2019-02-28
SG10202101247QA (en) 2021-03-30
ZA201900466B (en) 2020-06-24

Similar Documents

Publication Publication Date Title
MX379545B (es) Composiciones y metodos para el tratamiento del dolor cronico.
MX386467B (es) Composiciones y métodos para el tratamiento de xerostomia (sequedad bucal)
WO2013175377A3 (en) Compositions and methods for treatment of mucositis
WO2013175376A3 (en) Compositions and methods for the treatment of local pain
NZ701832A (en) Compositions and methods for treatment of inflammatory bowel disease
MX2022005523A (es) Composiciones y metodos para el tratamiento de infecciones fungicas.
WO2016046680A3 (en) Compositions and methods for the treatment of liver metabolic diseases
WO2014091384A3 (en) Compositions and methods for the treatment of mucositis
WO2014068463A3 (en) Compositions and methods for the treatment of inflammation and metabolic disorders
MX2019001360A (es) Composiciones y metodos para el tratamiento de sindrome de intestino irritable.
MX384144B (es) Composiciones y métodos para el tratamiento del cáncer.
WO2013175359A3 (en) Compositions and methods for the treatment of multiple sclerosis
WO2020075023A3 (en) Compositions and methods for the treatment of parkinson's disease
WO2014087307A3 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
MX383090B (es) Composiciones y métodos para el tratamiento de enfermedades infecciosas orales.
WO2014087323A3 (en) Compounds and compositions for the treatment of autoimmune and chronic metabolic diseases
MX386208B (es) Composiciones y métodos para el tratamiento de pólipos gastrointestinales.
MX2015008661A (es) Proceso para la obtencion de un derivado de fluorlactona.
WO2015028976A3 (en) Compounds and methods for the treatment of inflammatory diseases
SG10201906474QA (en) Compositions and methods for the treatment of mucositis
MX2021000740A (es) Composiciones y metodos para el tratamiento del cancer.
WO2017208088A3 (en) Compositions and methods for the treatment of parkinson's disease
WO2014037834A3 (en) Compositions and methods for treatment of inflammation and lipid disorders
WO2014037833A3 (en) Compositions and methods for treatment of inflammation and lipid disorders
NZ736131A (en) Compositions and methods for the treatment of epilepsy and neurological disorders